METHOD OF NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS SUFFERING FROM THORACIC ESOPHAGUS CANCER Russian patent published in 2009 - IPC A61K31/282 A61N5/67 A61K31/513 A61K31/519 A61K33/06 A61P35/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, oncology and to be used for neoadjuvant chemoradiotherapy in the patients suffering from thoracic oesophagus cancer. Said therapy is ensured by introduction of cisplatin and leucovorin, and continuous intravenous infusions of fluorouracil dosed 300 mg/m². Cisplatin solution is introduced intravenously drop-by-drop and dosed 6 mg/m² daily once a day within 1 hour. Leucovorin is injected intravenously jet-like and dosed 30 mg/m². Radiotherapy involves daily fractions 3 Gy to total basic dose 30 Gy. The course dose of fluorouracil is 3600 mg/m², of cisplatin is 72 mg/m², of leucovorin 360 mg/m². Chemotherapy and radiotherapy are to be started the same day.

EFFECT: disclosed method allows for considerably reduced toxicity of treatment to be continuous, treatment of the patients originally of bad performance status, for doubly reduced time of neoadjuvant treatment with maintaining high clinical effectiveness.

2 ex